Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: A phase II study

Cancer

Volumn 101, Issue 1, 2004, Pages 164-171

  Chang, Ting Chang ^a   Law, Kim Seng ^a   Hong, Ji Hong ^a   Lai, Chyong Huey ^a   Ng, Koon Kwan ^a   Hsueh, Suei ^a   See, Lai Chu ^b   Chang, Yu Chen ^a   Tsai, Chien Sheng ^a   Chou, Hung Hsueh ^a   Huang, Kuan Gen ^a   Liou, Jui Der ^a   Lin, Cheng Tao ^a   Chao, Angel ^a   Chen, Min Yu ^a   Wu, Tzu I ^a   Ma, Shih Ya ^a   Yen, Tzu Chen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cervical neoplasms; Computerized tomography; Overall survival; Positron emission tomography; Prospective studies; Recurrence; Squamous cell carcinoma antigen; Treatment outcome

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UTERINE CERVIX CANCER;

ANTIGENS, NEOPLASM; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; SERPINS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; UTERINE CERVICAL NEOPLASMS;

EID: 3042524186     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20349     Document Type: Article

References (24)

1. Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. J Epidemiol Biostat. 2000;24:7-43.
2. Sakurai H, Mitsuhashi N, Takahashi M, et al. Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone: patterns of recurrence, latent periods, and prognosis. Int J Radiat Oncol Biol Phys. 2001;50:1136-1144.
3. Sommers GM, Grigsby PW, Perez CA, et al. Outcome of recurrent cervical carcinoma following definitive irradiation. Gynecol Oncol. 1989;35:150-155.
4. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977;40:1621-1628.
5. Chan YM, Ng TY, Ngan HY, Wong LC. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol. 2002;84:7-11.
6. Esajas MD, Duk JM, de Bruijn HW, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol. 2001;19:3960-3966.
7. Lozza L, Merola M, Fontanelli R, et al. Cancer of the uterine cervix: clinical value of squamous cell carcinoma antigen (SCC) measurements. Anticancer Res. 1997;17:525-529.
8. Micke O, Prott FJ, Schafer U, Tangerding S, Potter R, Willich N. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 2000;20:5113-5115.
9. Bolli JA, Doering DL, Bosscher JR, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 1994;55:169-173.
10. Chou HH, Wang CC, Lai CH, et al. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys. 2001;51:442-448.
11. Larson DM, Copeland LJ, Stringer CA, Gershenson DM, Malone JM Jr., Edwards CL. Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol. 1988;30:381-387.
12. Cave L. HCFA approves Medicare coverage of PET scans. J Natl Cancer Inst. 2001;93:177.
13. Digby W, Keppler J. The current status of positron emission tomography. Radiol Manage. 2000;22:37-40.
14. Grigsby PW, Siegel BA, Dehdashti F, Mutch DG. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys. 2003;55:907-913.
15. Yeh LS, Hung YC, Shen YY, Kao CH, Lin CC, Lee CC. Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings. Oncol Rep. 2002;9:1289-1292.
16. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol. 1999;17:41-45.
17. Nakamoto Y, Eisbruch A, Achtyes ED, et al. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol. 2002;84:289-295.
18. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology. 2001;218:776-782.
19. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med. 1999;40:1125-1131.
20. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-D- glucose positron emission tomography in cervical cancer. J Clin Oncol. 2003;21:3651-3658.
21. Tsai CC, Tsai CS, Ng KK, et al. The impact of image fusion in resolving discrepant findings between FDG-PET and MRI/CT in patients with gynaecological cancers. Eur J Nucl Med Mol Imaging. 2003;30:1674-1683.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
23. Maiman M. The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma. Gynecol Oncol. 2002;84:4-6.
24. Shirato H, Ichimura W, Wakushima H, Nishioka T, Suzuki K. Squamous cell carcinoma antigen in serum for monitoring of head and neck and uterine cervical squamous cell carcinomas after radiotherapy. Acta Oncol. 1993;32:663-666.